Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma

NCT03107962 is registered in ClinicalTrials.gov with Mingzhi Zhang as lead sponsor.

NCT NCT03107962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03107962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma
Lead sponsor
Mingzhi Zhang
Phase
Phase 2
Overall status
Unknown status
Start date
February 19, 2017
Completion date
December 31, 2018
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

natural killer/t-cell lymphoma, nasal and nasal-type